MON1A inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of MON1A, a protein that plays a crucial role in the regulation of vesicle trafficking and endosomal maturation within cells. MON1A, part of the MON1-CCZ1 complex, is responsible for the transition of early endosomes into late endosomes by regulating the recruitment of Rab GTPases, which are key regulators of intracellular membrane transport. This process is essential for the proper sorting and delivery of cargo, including proteins and lipids, to their intended destinations within the cell, particularly to the lysosome for degradation or recycling. Inhibition of MON1A disrupts these trafficking pathways, impairing the endocytic and autophagic pathways, and leading to potential accumulation of undegraded materials in the cell. This makes MON1A inhibitors valuable tools for studying intracellular transport and vesicle maturation.
In research settings, MON1A inhibitors are used to explore the molecular mechanisms underlying endosomal maturation and the broader implications of disrupted vesicle trafficking on cellular homeostasis. By inhibiting MON1A, scientists can investigate how defects in the endosomal-lysosomal pathway affect the sorting and degradation of cellular components, particularly focusing on how the inhibition leads to altered protein and lipid recycling, autophagy, and organelle integrity. This inhibition allows researchers to study the downstream effects on processes such as nutrient sensing, signal transduction, and metabolic regulation, all of which are tightly connected to efficient endosomal maturation and trafficking. Additionally, MON1A inhibitors provide insights into the interactions between MON1A and other proteins involved in vesicle formation, shedding light on the complex networks that coordinate cellular transport systems. Through these studies, the use of MON1A inhibitors enhances our understanding of vesicular trafficking, endosomal maturation, and the broader impact of these processes on cell function and survival.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts the Golgi apparatus by inhibiting protein transport. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Ionophore that alters endosomal and lysosomal protein processing. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3 kinase inhibitor, affecting vesicle trafficking. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Inhibits dynamin, influencing endocytic vesicle formation. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Disrupts Golgi-to-ER trafficking. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Microtubule-depolymerizing agent, affecting vesicle movement. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Actin polymerization inhibitor, influencing vesicle trafficking. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Microtubule-disrupting agent, perturbing vesicle transport. | ||||||
Pitstop 2 | 1419320-73-2 | sc-507418 | 10 mg | $360.00 | ||
Inhibits clathrin-mediated endocytosis. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
Inhibits cytohesin ARF GEFs, impacting vesicle trafficking. | ||||||